Saudi Arabia Prescribing Information and Adverse Events Reporting
touchEXPERT BRIEFING Treating to Target in Homozygous Familial Hypercholesterolemia
Experts discuss diagnosis and management of homozygous familial hypercholesterolemia (HoFH), and its relevance in the Gulf Cooperation Council (GCC) region.
Prof. Naji Aljohani discusses the HoFH patient journey, from diagnosis, through standard-of-care (SoC) treatment options and long-term management.
1/2 Next InterviewIn this interview, we asked Prof. Naji Aljohani the following questions:
- Describe HoFH disease burden and treatment objectives / goals.
- Describe state of the art in HoFH management and limits of standard-of-care (SoC). How will recent updates to treatment guidelines for HoFH benefit patients suspected of having the condition?
- What are the long-term consequences (“complications”) of failing to achieve adequate LDL-C control?
- What are the main practical challenges for patients receiving current SoC therapies in the GCC region?
- Is there a local experience with lomitapide?
Prof. Naji Aljohani is a Consultant in Endocrinology and Thyroid Oncology at the Obesity, Endocrine and Metabolic Center, King Fahad Medical City. He also serves as Associate Professor at Alfaisal University.
Disclosures: Honoraria from Chiesi Farmaceutici S.p.A.
Prof. Naji Kholaif provides an overview of unmet needs and key issues affecting the diagnosis and management of HoFH in the GCC region.
2/2 Leave FeedbackIn this interview, we asked Prof. Naji Kholaif the following questions:
- Is there a disproportionately higher prevalence of HoFH in the GCC region, compared with the global picture?
- What factors can delay the diagnosis of HoFH?
- Given the high prevalence of consanguinity and the founder effect in the GCC region, is routine HoFH screening warranted?
- What are the possible barriers to screening uptake in the GCC region and the proposed solution?
- Liver transplants – could they cure HoFH patients?
Prof. Naji Kholaif is a Cardiology and Echocardiography Consultant at King Faisal Specialist Hospital and Research Center. He also serves as an Adjunct Assistant Professor at Alfaisal University.
After completing his residency training at Drexel University in Philadelphia, Prof. Kholaif pursued further specialization in Cardiology at the University of Alberta in Edmonton, Canada. He went on to earn a Master’s degree in Translational Medicine from the same institution. Prof. Kholaif holds American and Canadian board certifications in Internal Medicine, Cardiology, and Echocardiography.
Prof. Kholaif’s research interests are focused on Familial Hypercholesterolemia, Cardio-oncology, and Valvular Heart Disease in Pregnancy. He has recently published a registry on patients with Homozygous Familial Hypercholesterolemia.
Disclosures: Honoraria from Chiesi Farmaceutici S.p.A.
Overview & Learning Objectives
Overview
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetically inherited condition that results in extremely elevated low-density lipoprotein cholesterol (LDL-C) levels, accelerated atherosclerosis and premature cardiovascular disease (CVD).1,2 In this activity, experts review best practice in the management of HoFH, and discuss real-world and clinical experience with lomitapide in the Gulf Cooperation Council (GCC) region.
Learning Objectives
After watching this activity, participants should be better able to:
- Describe HoFH disease burden and treatment objectives / goals
- Understand the state of the art in HoFH management and limits of standard-of-care
- Discuss the need and role of lomitapide in HoFH management
- Review key clinical and real-world data supporting the use of lomitapide
Faculty & Disclosures
Prof. Naji Aljohani
Endocrinology and Thyroid Oncology Consultant, Obesity, Endocrine and Metabolic Center, King Fahad Medical City, & Associate Professor, Alfaisal University, Riyadh, Saudi Arabia
Prof. Naji Aljohani is a Consultant in Endocrinology and Thyroid Oncology at the Obesity, Endocrine and Metabolic Center, King Fahad Medical City. He also serves as Associate Professor at Alfaisal University.
Disclosures: Honoraria from Chiesi Farmaceutici S.p.A.
Prof. Naji Kholaif
Cardiology and Echocardiography Consultant, King Faisal Specialist Hospital and Research Center, & Adjunct Assistant Professor, Alfaisal University, Riyadh, Saudi Arabia
Prof. Naji Kholaif is a Cardiology and Echocardiography Consultant at King Faisal Specialist Hospital and Research Center. He also serves as an Adjunct Assistant Professor at Alfaisal University.
After completing his residency training at Drexel University in Philadelphia, Prof. Kholaif pursued further specialization in Cardiology at the University of Alberta in Edmonton, Canada. He went on to earn a Master’s degree in Translational Medicine from the same institution. Prof. Kholaif holds American and Canadian board certifications in Internal Medicine, Cardiology, and Echocardiography.
Prof. Kholaif’s research interests are focused on Familial Hypercholesterolemia, Cardio-oncology, and Valvular Heart Disease in Pregnancy. He has recently published a registry on patients with Homozygous Familial Hypercholesterolemia.
Disclosures: Honoraria from Chiesi Farmaceutici S.p.A.
Adverse Events
Adverse Events
To report Adverse Events:
The National Pharmacovigilance Centre (NPC)-Saudi Food and Drug Authority (SFDA)
SFDA call center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: http://ade.sfda.gov.sa/
Amryt Local Pharmacovigilance:
E-mail: qppv-saudi@pharmaknowl.com
Phone: +966112777729 / +966112404409
References
- D’Erasmo L, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan European retrospective observational study. Eur J Preventive Cardiol 2022; 29:832 841.
- Tromp TR, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 2022; 399:719 728.
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 9 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
